此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

关于健康成人流感改良 RNA 疫苗的研究

2026年6月9日 更新者:Pfizer

评估改良 RNA 流感疫苗对健康成年人的安全性、耐受性和免疫原性的研究

本研究的目的是了解用于预防流感的修饰 RNA (modRNA) 疫苗是否:

  • 安全的;和
  • 这些疫苗如何在一般健康的成年人中产生免疫反应。 免疫反应是身体保护自己免受其认为有害或异物侵害的方式。

RNA(也称为核糖核酸)是细胞产生的两种核酸之一。 RNA 包含从 DNA(另一种核酸)复制的信息。 细胞产生几种不同形式的RNA,每种形式在细胞中都有特定的作用。 许多形式的 RNA 都具有与制造蛋白质相关的功能。 RNA也是一些病毒的遗传物质,而不是DNA。 RNA 可以在实验室中制备并用于研究。 也称为核糖核酸。

流感是指流感疾病的术语。 这是一种由病毒引起的感染,会影响您的口腔、鼻子和喉咙。

该研究正在寻找以下参与者:

  • 年满 18 岁
  • 过去 6 个月内没有接种过流感疫苗
  • 总体健康

本研究将分为三个子研究:子研究 A (SSA)、子研究 B (SSB) 和子研究 C (SSC)。

所有参与者,无论子研究如何,都将接受 1 剂以下任一疫苗注射到手臂:

  • 1种正在研究的modRNA流感疫苗;或者
  • 批准用于各自年龄组的流感疫苗。

参与者将参与这项研究约 6 个月。 在此期间,参与者将至少进行 3 次门诊就诊。

研究概览

研究类型

介入性

注册 (实际的)

1202

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Mobile、Alabama、美国、36608
        • AMR Clinical
    • Arizona
      • Scottsdale、Arizona、美国、85260
        • Headlands Research - Scottsdale
    • California
      • Anaheim、California、美国、92801
        • Anaheim Clinical Trials, LLC
      • Lake Forest、California、美国、92630
        • Orange County Research Center
      • San Diego、California、美国、92103
        • Artemis Institute for Clinical Research
      • Walnut Creek、California、美国、94598
        • Diablo Clinical Research, Inc.
    • Connecticut
      • Milford、Connecticut、美国、06460
        • Clinical Research Consulting
    • Florida
      • Hialeah、Florida、美国、33012
        • Indago Research & Health Center, Inc
      • Hollywood、Florida、美国、33024
        • Research Centers of America
      • Hollywood、Florida、美国、33024
        • Research Centers of America ( Hollywood )
      • Miami Lakes、Florida、美国、33014
        • Palm Springs Community Health Center
      • Orlando、Florida、美国、32801
        • Clinical Neuroscience Solutions, Inc.
      • Orlando、Florida、美国、32819
        • Headlands Research Orlando
      • South Miami、Florida、美国、33143
        • Qps-Mra, Llc
    • Hawaii
      • Honolulu、Hawaii、美国、96814
        • East-West Medical Research Institute
    • Louisiana
      • New Orleans、Louisiana、美国、70119
        • Alliance for Multispecialty Research, LLC
    • Minnesota
      • Saint Paul、Minnesota、美国、55114
        • Prism Research LLC dba Nucleus Network
    • Missouri
      • Chesterfield、Missouri、美国、63005
        • Clinical Research Professionals
      • Kansas City、Missouri、美国、64114
        • Alliance for Multispecialty Research, LLC
    • New York
      • Rochester、New York、美国、14609
        • Rochester Clinical Research, LLC
    • North Carolina
      • Durham、North Carolina、美国、27703
        • Duke Vaccine and Trials Unit
      • Raleigh、North Carolina、美国、27612
        • M3 Wake Research, Inc.
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • DM Clinical Research - Philadelphia
    • Texas
      • Brownsville、Texas、美国、78526
        • Headlands Horizons LLC
      • Mesquite、Texas、美国、75149
        • SMS Clinical Research
      • San Antonio、Texas、美国、78229
        • Clinical Trials of Texas, LLC
      • San Antonio、Texas、美国、78229
        • Clinical Trials of Texas, LLC dba Flourish Research
      • Tomball、Texas、美国、77375
        • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    • Utah
      • Salt Lake City、Utah、美国、84109
        • J. Lewis Research, Inc. / Foothill Family Clinic
      • Salt Lake City、Utah、美国、84121
        • J. Lewis Research, Inc. / Foothill Family Clinic South
    • Virginia
      • Charlottesville、Virginia、美国、22911
        • Charlottesville Medical Research
      • Norfolk、Virginia、美国、23502
        • AMR Clinical

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

主要纳入标准

适用于所有 3 个子研究:

  • 参与者年龄≥18岁。
  • 一般健康的参与者。

仅子研究 C:

- 至少 6 个月前收到 2023-2024 年流感季节的许可流感疫苗接种。

主要排除标准

所有 3 个子研究:

  • 过去 6 个月内诊断出流感(通过临床检测)。
  • 已知或疑似免疫缺陷的免疫功能低下个体
  • 6 个月内收到任何研究性或许可的流感疫苗。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:SSA:流感 ModRNA 疫苗 2A
- 第一天单剂
肌内注射
实验性的:SSA:流感 ModRNA 疫苗 3A
- 第一天单剂
肌内注射
实验性的:SSA:流感 ModRNA 疫苗 4A
- 第一天单剂
肌内注射
实验性的:SSA:流感 ModRNA 疫苗 5A
- 第一天单剂
肌内注射
有源比较器:SSA:QIV1
- 第一天单剂
肌内注射
实验性的:SSB:流感 ModRNA 疫苗 3B
- 第一天单剂
肌内注射
实验性的:SSB:流感 ModRNA 疫苗 4B
- 第一天单剂
肌内注射
实验性的:SSB:流感 ModRNA 疫苗 5B
- 第一天单剂
肌内注射
有源比较器:单边带:QIV2
- 第一天单剂
肌内注射
有源比较器:单边带:QIV3
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 3C
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 4C
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 5C
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 6C
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 7C
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 8C
- 第一天单剂
肌内注射
实验性的:SSC:流感 ModRNA 疫苗 9C
- 第一天单剂
肌内注射
有源比较器:SSC:QIV2
- 第一天单剂
肌内注射
有源比较器:SSC:QIV3
- 第一天单剂
肌内注射

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
SSA: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination
大体时间:From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Local reactions included pain at the injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. All local reactions were graded based on center for biologics evaluation and research (CBER) toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any local reaction of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSB: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination
大体时间:From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Local reactions included pain at the injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. All local reactions were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any local reaction of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSC: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination
大体时间:From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Local reactions included pain at the injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. All local reactions were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any local reaction of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSA: Percentage of Participants With Systemic Events for up to 7 Days Following Vaccination
大体时间:From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain and joint pain) were recorded by participants in the e-diary or by investigators in CRF after vaccination. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any systemic events of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSB: Percentage of Participants With Systemic Events for up to 7 Days Following Vaccination
大体时间:From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain and joint pain) were recorded by participants in the e-diary or by investigators in CRF after vaccination. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any systemic events of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSC: Percentage of Participants With Systemic Events for up to 7 Days Following Vaccination
大体时间:From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain and joint pain) were recorded by participants in the e-diary or by investigators in CRF after vaccination. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any systemic events of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination
大体时间:From study vaccination on Day 1 through 4 weeks after study vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
From study vaccination on Day 1 through 4 weeks after study vaccination
SSB: Percentage of Participants With AEs From Vaccination Through 4 Weeks After Vaccination
大体时间:From study vaccination on Day 1 through 4 weeks after study vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
From study vaccination on Day 1 through 4 weeks after study vaccination
SSC: Percentage of Participants With AEs From Vaccination Through 4 Weeks After Vaccination
大体时间:From study vaccination on Day 1 through 4 weeks after study vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
From study vaccination on Day 1 through 4 weeks after study vaccination
SSA: Percentage of Participants With SAEs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event judged by the investigator.
From study vaccination on Day 1 through 6 months after study vaccination
SSB: Percentage of Participants With SAEs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event judged by the investigator.
From study vaccination on Day 1 through 6 months after study vaccination
SSC: Percentage of Participants With SAEs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event judged by the investigator.
From study vaccination on Day 1 through 6 months after study vaccination
SSA: Percentage of Participants With Medically Attended Adverse Events (MAEs) From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
From study vaccination on Day 1 through 6 months after study vaccination
SSB: Percentage of Participants With MAEs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
From study vaccination on Day 1 through 6 months after study vaccination
SSC: Percentage of Participants With MAEs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
From study vaccination on Day 1 through 6 months after study vaccination
SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects (e.g., asthma).
From study vaccination on Day 1 through 6 months after study vaccination
SSB: Percentage of Participants With NDCMCs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects (e.g., asthma).
From study vaccination on Day 1 through 6 months after study vaccination
SSC: Percentage of Participants With NDCMCs From Vaccination Through 6 Months After Vaccination
大体时间:From study vaccination on Day 1 through 6 months after study vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects (e.g., asthma).
From study vaccination on Day 1 through 6 months after study vaccination

次要结果测量

结果测量
措施说明
大体时间
SSA: Geometric Mean Titers (GMTs) of Strain-Specific Hemagglutination Inhibition Assay (HAI) Titers at Baseline and 4 Weeks After Vaccination
大体时间:Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
SSA: Geometric Mean Fold Rise (GMFR) of Strain-Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination
大体时间:From before study vaccination on Day 1 up to 4 weeks after study vaccination
GMFR was defined as the geometric mean of the fold rise in the assay results from before vaccination to a specified time point after vaccination.
From before study vaccination on Day 1 up to 4 weeks after study vaccination
SSA: Percentage of Participants Achieving HAI Seroconversion for Each Strain at 4 Weeks After Vaccination
大体时间:4 weeks after study vaccination
Seroconversion was defined as an HAI titer <1:10 prior to vaccination and >=1:40 at the time point of interest, or an HAI titer of >=1:10 prior to vaccination with at least a 4-fold rise at the time point of interest.
4 weeks after study vaccination
SSA: Percentage of Participants With HAI Titers >=1:40 For Each Strain at Baseline and 4 Weeks After Vaccination
大体时间:Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
This measure is for percentage of participants achieving HAI titers >=1:40 for each strain.
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
SSB: GMTs of Strain-Specific HAI Titers at Baseline and 4 Weeks After Vaccination
大体时间:Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
SSB: GMFRs of Strain-Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination
大体时间:From before study vaccination on Day 1 up to 4 weeks after study vaccination
From before study vaccination on Day 1 up to 4 weeks after study vaccination
SSB: Percentage of Participants Achieving HAI Seroconversion for Each Strain at 4 Weeks After Vaccination
大体时间:4 weeks after study vaccination
4 weeks after study vaccination
SSB: Percentage of Participants With HAI Titers >=1:40 For Each Strain at Baseline and 4 Weeks After Vaccination
大体时间:Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
This measure is for percentage of participants achieving HAI titers >=1:40 for each strain.
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年5月23日

初级完成 (实际的)

2025年2月5日

研究完成 (实际的)

2025年2月5日

研究注册日期

首次提交

2024年5月24日

首先提交符合 QC 标准的

2024年5月30日

首次发布 (实际的)

2024年5月31日

研究记录更新

最后更新发布 (实际的)

2026年6月12日

上次提交的符合 QC 标准的更新

2026年6月9日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • C4781013
  • NCT06436703 (注册表标识符:ClinicalTrials.gov)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

辉瑞将提供对个人去识别化参与者数据和相关研究文件(例如, 根据合格研究人员的要求,并遵守某些标准、条件和例外情况,提供协议、统计分析计划 (SAP)、临床研究报告 (CSR)。 有关辉瑞数据共享标准和请求访问流程的更多详细信息,请访问:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests。

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅